Heads up: we show every live trademark, plus inactive ones from the last 5 years, in the United States, Singapore, Canada, Australia and France. India is looked up live when you search, so it is not a saved copy of every mark, and it can be busy some days. Data is only as fresh as each country publishes it, and some countries aren’t included yet, so a brand can be registered even if it doesn’t show here. Always check the official record before you use a name. This is not legal advice.
MODE
Fifth Extension - Granted
Show more
Class 5: Pharmaceutical products, namely, multifunctional molecules that bind to extracellular circulating disease-causing proteins and other biomolecules and target them for lysosomal degradation, for use in the treatment of autoimmune disorders, inflammatory diseases and conditions, metabolic disorders, allergies, cancers, infectious diseases, and neurological disorders
Class 42: Discovery in the nature of pharmaceutical research, development, engineering and testing, namely, for multifunctional molecules that bind to extracellular circulating disease-causing proteins and other biomolecules and target them for lysosomal degradation, for use in the treatment of autoimmune disorders, inflammatory diseases and conditions, metabolic disorders, allergies, cancers, infectious diseases, and neurological disorders
Class 5 – Pharmaceuticals & supplementsClass 42 – Technology & SaaS
Status timeline
- 4 Aug 2023Application filedNew Application Entered
- 23 Sep 2023Assigned to an examining attorneyAssigned To Examiner
- 25 Sep 2023Approved for publicationApproved For Pub - Principal Register
- 31 Oct 2023Published for oppositionPublished For Opposition
- 26 Dec 2023Notice of allowance issued — statement of use requiredNoa Mailed - Sou Required From Applicant
- 5 Jan 2024Assigned to an examining attorneyAssigned To Examiner
- 2 Apr 2024Statement-of-use extension 1 grantedSou Extension 1 Granted
- 13 Dec 2024Statement-of-use extension 2 grantedSou Extension 2 Granted
- 23 May 2025Statement-of-use extension 3 grantedSou Extension 3 Granted
All 36 events
| 2026-08-22 | Notice Of Approval Of Extension Request E-Mailed |
| 2026-08-21 | Case Assigned To Intent To Use Paralegal |
| 2026-08-21 | Sou Extension 5 Granted |
| 2026-06-25 | Sou Teas Extension Received |
| 2026-06-25 | Sou Extension 5 Filed |
| 2026-03-27 | Teas Change Of Owner Address Received |
| 2026-03-27 | Applicant/Correspondence Changes (Non-Responsive) Entered |
| 2026-03-27 | Teas Change Of Correspondence Received |
| 2025-12-11 | Notice Of Approval Of Extension Request E-Mailed |
| 2025-12-10 | Sou Teas Extension Received |
| 2025-12-10 | Sou Extension 4 Filed |
| 2025-12-10 | Sou Extension 4 Granted |
| 2025-05-24 | Notice Of Approval Of Extension Request E-Mailed |
| 2025-05-23 | Sou Teas Extension Received |
| 2025-05-23 | Sou Extension 3 Filed |
| 2025-05-23 | Sou Extension 3 Granted |
| 2025-03-03 | Notice Of Approval Of Extension Request E-Mailed |
| 2024-12-13 | Sou Extension 2 Granted |
| 2024-12-12 | Sou Teas Extension Received |
| 2024-12-12 | Sou Extension 2 Filed |
| 2024-04-03 | Notice Of Approval Of Extension Request E-Mailed |
| 2024-04-02 | Sou Teas Extension Received |
| 2024-04-02 | Sou Extension 1 Filed |
| 2024-04-02 | Sou Extension 1 Granted |
| 2024-01-05 | Assigned To Examiner |
| 2023-12-26 | Noa Mailed - Sou Required From Applicant |
| 2023-11-29 | Teas Change Of Owner Address Received |
| 2023-11-29 | Applicant/Correspondence Changes (Non-Responsive) Entered |
| 2023-11-29 | Teas Change Of Correspondence Received |
| 2023-10-31 | Published For Opposition |
| 2023-10-31 | Official Gazette Publication Confirmation E-Mailed |
| 2023-10-11 | Notification Of Notice Of Publication E-Mailed |
| 2023-09-25 | Approved For Pub - Principal Register |
| 2023-09-23 | Assigned To Examiner |
| 2023-08-30 | New Application Office Supplied Data Entered |
| 2023-08-04 | New Application Entered |
Goods & services by class
Class 5 Pharmaceuticals & supplements
Pharmaceutical products, namely, multifunctional molecules that bind to extracellular circulating disease-causing proteins and other biomolecules and target them for lysosomal degradation, for use in the treatment of autoimmune disorders, inflammatory diseases and conditions, metabolic disorders, allergies, cancers, infectious diseases, and neurological disorders
Class 42 Technology & SaaS
Discovery in the nature of pharmaceutical research, development, engineering and testing, namely, for multifunctional molecules that bind to extracellular circulating disease-causing proteins and other biomolecules and target them for lysosomal degradation, for use in the treatment of autoimmune disorders, inflammatory diseases and conditions, metabolic disorders, allergies, cancers, infectious diseases, and neurological disorders
Owner details
See the official record for contact details. View official record →
Source & freshness
Source: the official United States trademark register. This record was last updated on 22 Aug 2026; the index was built on 20 Nov 2026 and covers data through 31 Aug 2026. View official record → If the two differ, the official record is correct.